Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MGB-BP-3 in Healthy Men
NCT02518607Phase 1Completed
- Sponsor
- MGB Biopharma
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of MGB-BP-3 in Clostridioides difficile infection (CDI) (4 arms), sponsored by MGB Biopharma. Primary endpoint: Safety and Tolerability of single and repeated oral doses at 4 months. Started Jul 2015; status: completed.
02
Drugs
MGB-BP-3
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02518607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518607.